S&P Futures
4,295.50 -2.75 (-0.06%) Dow Futures
33,867.00 -6.00 (-0.02%) Nasdaq Futures
13,668.75 -12.50 (-0.09%) Russell 2000 Futures
2,023.10 -0.70 (-0.03%) Crude Oil
88.89 -0.52 (-0.58%) Gold
1,797.40 -0.70 (-0.04%)
CureVac N.V. (CVAC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 13.48 |
| Open | 13.47 |
| Bid | 13.11 x 800 |
| Ask | 13.79 x 1300 |
| Day's Range | 13.25 - 13.63 |
| 52 Week Range | 12.39 - 75.68 |
| Volume | |
| Avg. Volume | 617,556 |
| Market Cap | 2.503B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.V. (NASDAQ: CVAC). CureVac, earlier this month, filed a lawsuit in Germany against BioNTech over its use of mRNA technology. Related: CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech. It did not rule out further legal action against BioNTech's p
- Reuters
UPDATE 2-BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit https://tmsnrt.rs/3PAjBo7, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.
- Reuters
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.
